Acid‐inhibitory effects of omeprazole and lansoprazole in <i>Helicobacter pylori</i>‐negative healthy subjects

Geus, W. P.; Mulder, Paul; Nicolai, J. J.; Boomgaard, D. M. Van Den

doi:10.1046/j.1365-2036.1998.00304.x

Cited by 24 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subjects with negative H. pylori urea breath test and known CYP2C19 status arrived at the pH laboratory of the clinic by 08:30 hours. pH measurements were performed as previously described 6, 15 . pH recordings started at 08:55 hours (day 0).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

Hunfeld

Touw

Mathôt³

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…The pH electrode was removed at 08:55 hours (day 6) and the position of the assembly was checked prior to removal. Standard meals and drinks were provided as previously described 6, 15 …”

Section: Methodsmentioning

confidence: 99%

A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

Hunfeld

Touw

Mathôt³

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Tolman et al [7] demonstrated higher antisecretory efficacy with L30 than with O20, whereas Seensalu et al [8], Verdu et al [9], and Geus et al [10] found that the acid-decreasing effects of L30 and O20 were comparable. In the crossover study of Dammann et al [11], the order of antisecretory potency of the PPIs was L30=O40>L15=O20.…”

Section: Pharmacodynamics: Effect Of Ppis On Acid Secretion In Humansmentioning

confidence: 95%

Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole

Thomson

2000

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Four proton pump inhibitors (PPIs) are currently marketed in various parts of the world, and all of these (lansoprazole, omeprazole, pantoprazole, and rabeprazole) are available for prescription use in the United States. As a therapeutic group, the PPIs are highly useful for the relief of symptoms and healing of gastroesophageal reflux disease, gastric and duodenal ulcer disease, eradication of Helicobacter pylori infection, prevention and treatment of nonsteroidal anti-inflammatory drug (NSAID)-associated damage, management of hypersecretory states such as Zollinger-Ellison syndrome, and care of patients with non-variceal upper gastrointestinal bleeding, or non-ulcer dyspepsia. The pathophysiologic basis of these management benefits lies in the potent gastric acid inhibitory effects of the PPIs. There are differences between the PPIs in their pharmacokinetics, pharmacodynamics, influence by food and antacids, clinical efficacy, and potential for drug interactions. It is not always clear whether these often subtle variations are necessarily of clinical importance. The physician's choice of one PPI over another must rest with her/his interpretation of the clinical importance of the generally small differences between PPIs, their approval for treatment of specific clinical indications within the physician's practice jurisdiction, and the strength of the evidence based on the quantity and quality of the supporting clinical trials.

show abstract

“…However, many other studies comparing omeprazole and lansoprazole have shown no significant difference overall in any pH parameters [48,49]. Pantoprazole (40 mg) has also been compared with omeprazole (20 mg); the results showed a significantly higher daytime and 24-hour pH with pantoprazole [50].…”

Section: Comparing the Efficacy Of Ppismentioning

confidence: 99%

Pharmacology of proton pump inhibitors

Shin

Sachs

2008

Curr Gastroenterol Rep

381

329

View full text Add to dashboard Cite

The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are weak bases composed of two moieties, a substituted pyridine with a primary pK a of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole with a second pK a of about 1.0. PPIs are acid-activated prodrugs that convert to sulfenic acids or sulfenamides that react covalently with one or more cysteines accessible from the luminal surface of the ATPase. Because of covalent binding, their inhibitory effects last much longer than their plasma half-life. However, the short half-life of the drug in the blood and the requirement for acid activation impair their efficacy in acid suppression, particularly at night. PPIs with longer half-life promise to improve acid suppression. All PPIs give excellent healing of peptic ulcers and produce good results in reflux esophagitis. PPIs combined with antibiotics eradicate Helicobacter pylori.

show abstract

Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjects

Cited by 24 publications

References 17 publications

A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole

Pharmacology of proton pump inhibitors

Contact Info

Product

Resources

About